RTEL1inHHS · Characterization of RTEL1 mutations in Hoyeraal-Hreidarsson Syndrome
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2017-01-01 → 2018-12-31
- EU contribution
- €183,455
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Characterization of RTEL1 mutations in Hoyeraal-Hreidarsson Syndrome
Telomeres, which are DNA sequences located at chromosome ends, are critically maintained through the activity of telomerase, which adds telomeric repeats to solve the end replication problem, and RTEL1, an enzyme that DNA secondary structures at telomeres to facilitate replication progression. With our work, we have demonstrated that, paradoxically, telomerase can contribute to telomere shortening by stabilising stalled replication forks at chromosome ends. Our research established reversed replication forks are a pathological substrate for telomerase and the source of telomere catastrophe in Rtel1 cells. Inhibiting telomerase recruitment to telomeres, but not inhibition of its activity, or blocking replication fork reversal prevents the rapid accumulation of dysfunctional telomeres in RTEL1-deficient cells. In this context, we established that telomerase binding to reversed replication forks inhibits telomere replication, which can be mimicked by preventing replication fork restart. Our results lead us to propose that telomerase inappropriately binds to and inhibits restart of reversed replication forks within telomeres, which compromises replication and leads to critically short telomeres.
Data: CORDIS, © European Union
Project objective
Hoyeraal-Hreidarsson syndrome (HHS) is a multisystem disorder with patients presenting inter-uterine growth retardation, immunodeficiency, and/or aplastic anaemia. Recently, mutations in RTEL1 have been shown to be causal for this disease. RTEL1 prevents genomic instability and maintains integrity of the telomeres by disassembling different secondary structures that arise during DNA replication, repair, and recombination.Although recent discoveries from the host lab and others have shed light on the function of RTEL1 in maintaining genome stability, many outstanding questions remain to be addressed. Currently very little is known about RTEL1 regulation or how it is dynamically recruited to replication forks and telomeres to execute its functions. Moreover, it is not known whether RTEL1 expression or recruitment is regulated by post-translational modifications. Of the 18 identified mutations, only two have been characterized. As these undefined mutations are causal for HHS and must therefore affect the RTEL1 function, their detailed characterization is likely to shed light on new aspects of its function and/or regulation. The main objective of this project is to characterize the undefined HHS mutations in RTEL1 and determine how they impair the physiological protein function, in vitro and in vivo.To this end, we will take advantage of a complementation system that permits the stable expression of RTEL1 variants in RTEL1 deficient cells, allowing us to study RTEL1 mutant contribution to RTEL1 phenotypes. We will also perform comparative proteomic analysis of the mutants to determine if they abolish specific/novel protein-protein interactions. HHS mutations that present with a defined phenotype or affect a novel interaction will be studied in vivo in a mouse model. In summary, we anticipate that the combination of approaches proposed here holds the potential to significantly contribute towards the understanding of how different mutations affect RTEL1 function.
Original text from CORDIS.
Participants
- THE FRANCIS CRICK INSTITUTE LIMITED · LondonCoordinatorUnited Kingdom
Links
Data: CORDIS, © European Union